Teva sues Mylan over Copaxone patent infringement

Teva has sued Mylan for alleged patent infringement over Copaxone (glatiramer acetate injection), a treatment for patients with relapsing-remitting forms of multiple sclerosis.

The case, which was filed yesterday, January 17, at the US District Court for the Northern District of West Virginia, followed Mylan’s alleged continuing attempts to market a generic version of Copaxone.

The patent involved is US number 9,155,775, titled “Process for manufacturing glatiramer acetate product”. It expires in January 2035 and is owned by Teva.

According to the complaint, Mylan allegedly intends to launch the generic version of the drug upon receiving approval from the Food and Drug Administration.

Mylan has further allegedly stated that it is working towards January 28, 2017 as its target date for Abbreviation New Drug Application approval.

Teva has asked the court for a judgment that the ‘775 patent was infringed and is valid.

It has also asked the court for a preliminary and permanent injunction enjoining Mylan from marketing the generic drug, as well as an award of damages.

In a separate case, which was ruled on in August 2016, Mylan invalidated two of Teva’s patents covering Copaxone in a US Patent and Trademark Office inter partes review proceeding.